The next few months will be critical in developing interest from prospective shareholders.
Although for NY, I do believe that the shareholder value is important but what is most important is building the value piece by piece for that end buyer.
It may sound cliche although NY hasn't spent a decade on this to settle for minimal value.
Either way, we should see the turning point for both in the near term.
- Forums
- ASX - By Stock
- Ann: NZ Investor Presentation
The next few months will be critical in developing interest from...
Featured News
Add EXR (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $63.43M |
Open | High | Low | Value | Volume |
5.2¢ | 5.4¢ | 5.2¢ | $75.87K | 1.449M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 819274 | 5.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.3¢ | 13471 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 819274 | 0.051 |
21 | 2488119 | 0.050 |
3 | 265346 | 0.049 |
4 | 229354 | 0.048 |
2 | 113850 | 0.047 |
Price($) | Vol. | No. |
---|---|---|
0.053 | 13471 | 1 |
0.054 | 527750 | 3 |
0.055 | 330000 | 3 |
0.057 | 219867 | 2 |
0.058 | 62631 | 2 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
EXR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online